Prognostic value of the veterans affairs frailty index in older patients with non-small cell lung cancer

被引:10
|
作者
Cheng, David [1 ,2 ]
Dumontier, Clark [2 ,3 ,4 ]
Sheikh, Ayesha R. [5 ]
La, Jennifer [3 ]
Brophy, Mary T. [3 ,6 ]
Do, Nhan, V [3 ,6 ]
Driver, Jane A. [2 ,3 ,6 ,7 ]
Tuck, David P. [3 ,6 ]
Fillmore, Nathanael R. [2 ,3 ,7 ]
机构
[1] Massachusetts Gen Hosp, Boston, MA 02114 USA
[2] Harvard Med Sch, Dept Med, Boston, MA USA
[3] VA Boston Healthcare Syst, Boston, MA USA
[4] Brigham & Womens Hosp, Boston, MA 02115 USA
[5] St Vincent Hosp, Worcester, MA 01604 USA
[6] Boston Univ, Boston, MA 02215 USA
[7] Dana Farber Canc Inst, Boston, MA 02115 USA
来源
CANCER MEDICINE | 2022年 / 11卷 / 15期
关键词
electronic health records; frailty; non-small cell lung; prognosis; veterans; COMPREHENSIVE GERIATRIC ASSESSMENT; CARE; ONCOLOGY; ACCUMULATION; MORTALITY; CONSENSUS; SURVIVAL; CURVES; ADULTS;
D O I
10.1002/cam4.4658
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Older patients with non-small cell lung cancer (NSCLC) are a heterogeneous population with varying degrees of frailty. An electronic frailty index such as the Veterans Affairs Frailty Index (VA-FI) can potentially help identify vulnerable patients at high risk of poor outcomes. Methods NSCLC patients >= 65 years old and diagnosed in 2002-2017 were identified using the VA Central Cancer Registry. The VA-FI was calculated using administrative codes from VA electronic health records data linked with Medicare and Medicaid data. We assessed associations between the VA-FI and times to mortality, hospitalization, and emergency room (ER) visit following diagnosis by Kaplan-Meier analysis and multivariable stratified Cox models. We also evaluated the change in discrimination and calibration of reference prognostic models after adding VA-FI. Results We identified a cohort of 42,204 older NSCLC VA patients, in which 55.5% were classified as frail (VA-FI >0.2). After adjustment, there was a strong association between VA-FI and the risk of mortality (HR = 1.23 for an increase of four deficits or, equivalently, an increase of 0.129 on VA-FI, p < 0.001), hospitalization (HR = 1.16 for four deficits, p < 0.001), and ER visit (HR = 1.18 for four deficits, p < 0.001). Adding VA-FI to baseline prognostic models led to statistically significant improvements in time-dependent area under curves and did not have a strong impact on calibration. Conclusion Older NSCLC patients with higher VA-FI have significantly elevated risks of mortality, hospitalizations, and ER visits following diagnosis. An electronic frailty index can serve as an accessible tool to identify patients with vulnerabilities to inform clinical care and research.
引用
收藏
页码:3009 / 3022
页数:14
相关论文
共 50 条
  • [31] The Significance of the Prognostic Nutritional Index in Patients with Completely Resected Non-Small Cell Lung Cancer
    Mori, Shunsuke
    Usami, Noriyasu
    Fukumoto, Koichi
    Mizuno, Tetsuya
    Kuroda, Hiroaki
    Sakakura, Noriaki
    Yokoi, Kohei
    Sakao, Yukinori
    PLOS ONE, 2015, 10 (09):
  • [32] High prognostic nutritional index (PNI) as a positive prognostic indicator for non-small cell lung cancer patients with bone metastasis
    Xu, Shanqi
    Cao, Shoubo
    Geng, Jianxiong
    Wang, Chunyan
    Meng, Qingwei
    Yu, Yan
    CLINICAL RESPIRATORY JOURNAL, 2021, 15 (02): : 225 - 231
  • [33] Prognostic value of HMGB3 expression in patients with non-small cell lung cancer
    Song, Ning
    Liu, Bao
    Wu, Jian-Ling
    Zhang, Rui-Fang
    Duan, Lin
    He, Wen-Shu
    Zhang, Cong-Min
    TUMOR BIOLOGY, 2013, 34 (05) : 2599 - 2603
  • [34] Prognostic value of the expression of estrogen receptor β in patients with non-small cell lung cancer: a meta-analysis
    Ma, Lihong
    Zhan, Ping
    Liu, Yafang
    Zhou, Zejun
    Zhu, Qingqing
    Miu, Yingying
    Wang, Xiaoxia
    Jin, Jiajia
    Li, Qian
    Lv, Tangfeng
    Song, Yong
    TRANSLATIONAL LUNG CANCER RESEARCH, 2016, 5 (02) : 202 - 207
  • [35] Prognostic value of the pretreatment systemic immune-inflammation index (SII) in patients with non-small cell lung cancer: a meta-analysis
    Wang, Yan
    Li, Yina
    Chen, Pingrun
    Xu, Wenying
    Wu, Yanming
    Che, Guowei
    ANNALS OF TRANSLATIONAL MEDICINE, 2019, 7 (18)
  • [36] Prognostic value of the apoptotic index analysed jointly with selected cell cycle regulators and proliferation markers in non-small cell lung cancer
    Dworakowska, Dorota
    Jassem, Ewa
    Jassem, Jacek
    Karmolinski, Andrzej
    Lapinski, Mariusz
    Tomaszewski, Dariusz
    Rzyman, Witold
    Jaskiewicz, Kazimierz
    Sworczak, Krzysztof
    Grossman, Ashley B.
    LUNG CANCER, 2009, 66 (01) : 127 - 133
  • [37] Editorial: Prognostic factors in non-small cell lung cancer
    Rahouma, Mohamed
    Baudo, Massimo
    Zhang, Jun
    Mutti, Luciano
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [38] Osteopontin is a prognostic biomarker in non-small cell lung cancer
    Rud, Ane Kongsgaard
    Boye, Kjetil
    Oijordsbakken, Miriam
    Lund-Iversen, Marius
    Halvorsen, Ann Rita
    Solberg, Steinar K.
    Berge, Gisle
    Helland, Aslaug
    Brustugun, Odd Terje
    Maelandsmo, Gunhild M.
    BMC CANCER, 2013, 13
  • [39] The prognostic value of 4.1 mRNA expression in non-small cell lung cancer
    Xiang, Yuying
    Shan, Feiyu
    Feng, Guan
    Guo, Kaibo
    Ruan, Shanming
    Huang, Dawei
    TRANSLATIONAL CANCER RESEARCH, 2021, 10 (03) : 1216 - 1228
  • [40] Overexpression of RhoE has a prognostic value in non-small cell lung cancer
    Zhang, Cuiyan
    Zhou, Fang
    Li, Ning
    Shi, Susheng
    Feng, Xiaoli
    Chen, Zhaoli
    Hang, Jie
    Qiu, Bin
    Li, Baozhong
    Chang, Sheng
    Wan, Junting
    Shao, Kang
    Xing, Xuezhong
    Tan, Xiaogang
    Wang, Zhen
    Xiong, Meihua
    He, Jie
    ANNALS OF SURGICAL ONCOLOGY, 2007, 14 (09) : 2628 - 2635